Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis makes competing bid for Zentiva

Sanofi-aventis has announced that it intends to make a bid of $1.7bn for the Czech generic drug manufacturer, Zentiva
Sanofi-aventis has announced that it intends to make a bid of $1.7bn for the Czech generic drug manufacturer, Zentiva, outbidding an earlier offer from Czech financial group PPF.

Paris-based sanofi-aventis already holds a 24.9 per cent share in Zentiva while PPF, together with Italian insurer Generali, owns 19.2 per cent. The offer from sanofi-avensis is 10.5 per cent higher than the initial bid from the Czech financial house.

The acquisition of Zentiva would give the French pharmaceutical company more than 180 generic medicines, an area of the market growing at twice the rate of patent-protected products.

Zentiva is a market leader in the Czech Republic, Turkey, Romania and Slovakia, with a growing presence in Poland, Russia, Bulgaria, the Ukraine and the Baltic countries. Sanofi-aventis is already established in many of these markets and says that acquiring control of the generics manufacturer "carries a strong strategic rationale."

18th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics